Group 1: Business Growth and Strategy - The company has actively expanded its aircraft engine tooling sector, establishing a complete business chain in the aviation and aerospace fields through efficient resource integration and technological collaboration [3] - The demand for tooling is increasing due to the domestic aviation equipment upgrade and the acceleration of the localization process in the aerospace industry, positioning the company for market share breakthroughs [3] Group 2: UAV Production Advantages - The company leverages its deep technical foundation in forming tools and aerospace components to establish a comprehensive manufacturing system for UAVs, ensuring a closed-loop service from initial design to final product delivery [4] - This integrated approach enhances product precision and delivery efficiency while reducing production costs, creating a competitive edge in the high-end UAV market [4] Group 3: Tianjin Yuefeng's Business Scope and Future Plans - Tianjin Yuefeng focuses on the precision manufacturing of structural components for launch vehicles, covering processes such as metal heat treatment and precision machining [4] - The company has developed a full industrial chain business system, ensuring a comprehensive service from component processing to final product delivery [4] Group 4: Competitive Advantages in Aerospace Equipment - The company has established a full industrial chain layout, providing integrated solutions from design to delivery, with a focus on aerospace tooling and composite materials [6] - Long-term strategic partnerships with major domestic manufacturers and military research institutions ensure stable customer resources [6] - A highly experienced R&D team and strict quality management standards enhance the company's ability to meet high-end aerospace requirements [6] Group 5: Capital Increase and Cost Optimization - The current capital increase project focuses on enhancing large aircraft production capabilities and technological upgrades, progressing as planned [6] - To optimize costs, the company aims to innovate through new material applications and advanced manufacturing processes, while also strengthening supplier relationships to secure better procurement conditions [7]

Core Viewpoint - Guanglian Aviation plans to transfer a total of 10% equity in Chengdu Hangxin for a total price of 40 million yuan, while maintaining control over the subsidiary after the transfer [1][2]. Group 1: Equity Transfer Details - The company intends to transfer 2.5% equity to Tianjin Ronghe, 1.25% to Pudong Intelligent Fund, 2.5% to Yida Xinhai, and 3.75% to Chengdu Yida Fund [1]. - After the transfer, Guanglian Aviation will hold 50.1% of Chengdu Hangxin, which will continue to be included in the consolidated financial statements [1]. Group 2: Chengdu Hangxin Overview - Chengdu Hangxin, established on November 27, 2015, specializes in manufacturing aviation components, intelligent tooling design, and manufacturing, and has strong R&D and service capabilities [1]. - Chengdu Hangxin is recognized as a national high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Sichuan Province [1]. Group 3: Financial Performance - Chengdu Hangxin is projected to achieve revenue of 165 million yuan and a net profit of 24.87 million yuan in 2024; for the first quarter of 2025, it reported revenue of 53.36 million yuan and a net profit of 8.84 million yuan [1]. Group 4: Strategic Investment Benefits - The introduction of strategic investors is expected to enhance Chengdu Hangxin's capital operation channels and improve funding efficiency for business expansion and R&D [2]. - The collaboration with investors will help optimize strategic layout and strengthen the company's position in the aerospace equipment manufacturing market [2]. Group 5: Company Positioning - Guanglian Aviation is a well-known private supplier of aerospace industrial supporting products in China, focusing on high-end equipment R&D, production, and manufacturing [2]. - The company’s products cover both military and civilian fields, with advanced processing technology for composite materials and components [2]. Group 6: Project Involvement - Guanglian Aviation participates in several large aircraft development projects approved by the state, including being a supplier for the C919 large passenger aircraft and the AG600 amphibious aircraft assembly line [3]. - The company has improved its rapid development capabilities for metal components and tooling products, ensuring smooth delivery of production tasks [3].

Group 1 - The company plans to transfer a total of 10.00% equity stake in Chengdu Hangxin, consisting of multiple transactions to different partners [1] - The total transaction price for the equity transfer is 40 million yuan [1] - After the completion of the equity transfer, the company will hold 50.10% equity in Chengdu Hangxin, maintaining it as a subsidiary [1]

| 证券代码：300900 | 证券简称：广联航空 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：123182 | 债券简称：广联转债 | | 广联航空工业股份有限公司 第四届董事会第十次会议决议公告 一、董事会会议召开情况 广联航空工业股份有限公司（以下简称公司）第四届董事会第十次会议通知 于2025年6月18日以书面及电话等方式向各位董事发出，会议于2025年6月18日以 现场会议结合通讯形式在公司会议室召开。本次会议由公司董事长王增夺先生召 集并主持，应出席会议的董事9人，实际出席会议的董事9人，公司监事及其他高 级管理人员列席了会议。 本次会议的召集、召开及表决符合《中华人民共和国公司法》（以下简称《公 司法》）及《广联航空工业股份有限公司章程》（以下简称《公司章程》）的有 关规定，会议合法有效。 二、董事会会议审议情况 1、审议通过《关于控股子公司股权转让引进战略投资者的议案》 1、《广联航空工业股份有限公司第四届董事会第十次会议决议》。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 经与会董事审议，认 ...

广联航空工业股份有限公司 关于控股子公司股权转让引进战略投资者的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、 交易事项概述 成都航新航空装备科技有限公司（以下简称成都航新或标的公司）系广联航 空工业股份有限公司（以下简称公司或广联航空）持有60.10%股权的控股子公司。 公司拟将持有的成都航新2.50%股权转让给天津融和致远航空装备合伙企业（有 限合伙）（以下简称天津融和）；拟将持有的成都航新1.25%股权转让给上海浦 东智能智造一期私募投资基金合伙企业（有限合伙）（以下简称浦东智能基金）； 拟将持有的成都航新2.50%股权转让给扬州高投毅达鑫海三期创业投资合伙企业 （有限合伙）（以下简称毅达鑫海）；拟将其持有的成都航新3.75%股权转让给 成都毅达交子环投兴华汇蓉壹号创业投资基金合伙企业（有限合伙）（以下简称 成都毅达基金）；本次拟转让成都航新的股权比例合计为10.00%（以下简称标的 股权），股权转让交易总价为4,000万元。上述股权转让完成后，公司持有成都航 新50.10%股权，成都航新仍为公司控股子公司，将继续纳入公司的合并报表范围。 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

证券代码：300900 证券简称：广联航空 公告编号：2025-058 债券代码：123182 债券简称：广联转债 广联航空工业股份有限公司 技术咨询、技术交流、技术转让、技术推广；信息技术咨询服务；模具制造；模 具销售；通用设备制造（不含特种设备制造）；汽轮机及辅机制造；汽轮机及辅 机销售；专用设备修理；专用设备制造（不含许可类专业设备制造）；通用设备 修理；机械零件、零部件销售；通用零部件制造。（除依法须经批准的项目外， 凭营业执照依法自主开展经营活动）许可项目：民用航空器零部件设计和生产； 民用航空器（发动机、螺旋桨）生产；民用航空器维修。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准） 二、备查文件 《成都航新航空装备科技有限公司营业执照》 特此公告。 广联航空工业股份有限公司 董事会 广联航空工业股份有限公司（以下简称公司）于2025年4月21日召开了第四 届董事会第四次会议，审议通过了《关于全资子公司股权转让引进战略投资者的 议案》，具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《广联航 空工业股份有限公司关于全资 ...

广联航空（300900）公告，控股子公司成都航新航空装备科技有限公司已完成工商变更登记，并获得由 成都市新都区政务服务管理和行政审批局颁发的新营业执照。此次变更涉及股权转让引进战略投资者的 相关事宜。 ...

关于控股子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广联航空工业股份有限公司（以下简称公司）于2025年4月21日召开了第四 届董事会第四次会议，审议通过了《关于全资子公司股权转让引进战略投资者的 议案》，具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《广联航 空工业股份有限公司关于全资子公司股权转让引进战略投资者的公告》（公告编 号：2025-026）。 成都航新航空装备科技有限公司（以下简称成都航新）近日已办理完成上述 股权转让等相关事宜的工商变更登记手续，并取得了由成都市新都区政务服务管 理和行政审批局颁发的《营业执照》。 | 证券代码：300900 | 证券简称：广联航空 公告编号：2025-058 | | --- | --- | | 债券代码：123182 | 债券简称：广联转债 | 广联航空工业股份有限公司 8、经营范围：一般项目：机械设备研发；软件开发；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；信息技术咨询服务；模具制造；模 具销售；通用设备制造（不含 ...

Investment Rating - The report rates the defense and military industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [2][29]. Core Insights - The defense and military sector has shown resilience, with the Shenwan Defense and Military Index rising by 2.13%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.03% [3][7]. - The report anticipates a growth cycle for Chinese military trade, driven by increased international recognition of Chinese military products amid geopolitical tensions [6]. - The fundamental changes in the military sector are expected to solidify the upward trajectory of the industry, particularly benefiting companies involved in consumable weapons as the military modernization efforts intensify [6]. - The report suggests increasing attention to the military sector, highlighting specific areas such as precision-guided weapons, underwater capabilities, and advancements in AI and robotics [6]. Market Review - The Shenwan Defense and Military Index outperformed the market, ranking third among 31 sectors with a 2.13% increase [3][7]. - Notable stock performances included Rongfa Nuclear Power, which surged by 31.79%, and Haige Communication, which rose by 16.34% [14][15]. - Conversely, stocks like Lijun Co. and Changchun Yidong experienced significant declines, with Lijun Co. dropping by 21.89% [15]. Valuation Changes - The current PE-TTM for the Shenwan Defense and Military sector stands at 74.13, indicating a high valuation relative to historical levels [15][21]. - The report notes a divergence in valuations among sub-sectors, with aerospace and aviation equipment showing relatively high PE valuations since 2020 [15][19]. Key Valuation Metrics - The report provides a detailed valuation table for key companies in the defense sector, indicating projected net profits and PE ratios for the years 2024 to 2027 [21][24].